Search results for "OUTCOME"

showing 10 items of 5148 documents

Lung Preservation With Perfadex or Celsior in Clinical Transplantation: A Retrospective Single-Center Analysis of Outcomes.

2015

BACKGROUND Despite improvement of lung preservation by the introduction of low-potassium dextran (LPD) solution, ischemia-reperfusion injury remains a major contributor to early post-lung transplant graft dysfunction and mortality. After favorable experimental data, Celsior solution was used in our clinical lung transplant program. Data were compared with our historic LPD cohort. METHODS Between January 2002 and January 2005, 209 consecutive lung transplantations were performed with LPD. These were compared to 208 transplants between February 2005 and September 2007 with Celsior. Endpoints included posttransplant PaO2/FiO2 ratio at different timepoints after intensive care unit (ICU) admiss…

AdultMalemedicine.medical_specialtyTime FactorsOrgan Preservation SolutionsBronchiolitis obliteransKaplan-Meier EstimateSingle CenterDisaccharidesDisease-Free Survivallaw.inventionElectrolytesGlutamateslawRisk FactorsGermanymedicineHumansHistidineMannitolCitratesProportional Hazards ModelsRetrospective StudiesTransplantationLungProportional hazards modelbusiness.industryRetrospective cohort studyOrgan PreservationLength of StayMiddle Agedmedicine.diseaseIntensive care unitGlutathioneRespiration ArtificialSurgeryTransplantationIntensive Care Unitsmedicine.anatomical_structureTreatment OutcomeCohortBronchiolitisFemalePrimary Graft DysfunctionbusinessLung TransplantationTransplantation
researchProduct

Long-term radiation exposure in patients undergoing EVAR: Reflecting clinical day-to-day practice to assess realistic radiation burden.

2018

Endovascular repair of aortic aneurysms (EVAR) has become an established treatment option currently applied in an increasing numbers of patients with aortic aneurysms. Advantages include reduced surgical trauma, procedural time, intensive care unit and hospital lengths of stay, blood loss as well as morbidity and mortality.The optimal imaging modalities in EVAR follow-up as well as the appropriate intervals between these follow-ups remain subject of controversial discussion. Objective of this study was the evaluation of the realistic radiation exposure and risk estimate postop EVAR treatment.Of the follow-ups required according to the surveillance schedule during the first year post-EVAR, o…

AdultMalemedicine.medical_specialtyTime FactorsPhysiology030204 cardiovascular system & hematology030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciencesAortic aneurysm0302 clinical medicinelawRisk FactorsPhysiology (medical)medicineHumansIn patientAgedAged 80 and overbusiness.industryTreatment optionsHematologyMiddle AgedRadiation Exposuremedicine.diseaseIntensive care unitTerm (time)Radiation exposureRisk EstimateTreatment OutcomeEmergency medicineFemaleDay to dayCardiology and Cardiovascular MedicinebusinessAortic Aneurysm AbdominalClinical hemorheology and microcirculation
researchProduct

[Inferior vena cava malformations and deep venous thrombosis].

2006

We carried out a prospective study of 116 patients under 50 years of age who had deep venous thrombosis of the lower extremities to determine whether the presence of congenital anomaly of the inferior vena cava (IVC) was a risk factor for the disease. All patients were investigated by Doppler echography. Some 37 patients who had iliac vein occlusion also underwent phlebography. In 10 patients in whom the IVC was difficult to image, magnetic resonance angiography or computerized axial tomography was carried out. In all patients, studies of antithrombin, protein C and protein S deficiency, factor V Leiden, prothrombin G20210A, antiphospholipid antibodies, and acquired risk factors were also p…

AdultMalemedicine.medical_specialtyTime FactorsPopliteal VeinFemoral veinVena Cava InferiorIliac VeinInferior vena cavaRecurrenceRisk FactorsmedicineFactor V LeidenConfidence IntervalsHumansProtein S deficiencyProspective StudiesVenous ThrombosisLegbusiness.industryAnticoagulantsUltrasonography DopplerGeneral MedicinePhlebographyFemoral VeinMiddle Agedmedicine.diseaseThrombosisVein occlusionSurgeryVenous thrombosisTreatment Outcomemedicine.veincardiovascular systemProthrombin G20210AFemaleRadiologybusinessTomography X-Ray ComputedMagnetic Resonance AngiographyFollow-Up StudiesRevista espanola de cardiologia
researchProduct

GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controll…

2009

Objective To assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles. Design Single-center, randomized, single-blind, placebo-controlled trial. Setting University-affiliated infertility clinic, between February 2005 and December 2007. Patient(s) Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication. Intervention(s) Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n = 172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time. Main Outcome Measure(s) Pregnancy rate was the primary outcom…

AdultMalemedicine.medical_specialtyTime FactorsPregnancy Ratemedicine.medical_treatmentLuteal phaseDrug Administration Schedulelaw.inventionMiscarriageGonadotropin-Releasing HormonePlacebosRandomized controlled triallawPregnancyMedicineHumansSingle-Blind MethodEmbryo ImplantationInsemination ArtificialGynecologyPregnancyTriptorelin Pamoatebusiness.industryObstetricsArtificial inseminationUterusPregnancy OutcomeObstetrics and GynecologyFertility Agents Femalemedicine.diseaseTriptorelinPregnancy rateReproductive MedicineGestationFemalebusinessAlgorithmsmedicine.drugFertility and sterility
researchProduct

Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression

2009

Abstract Background There is substantial evidence that early improvement (EI) under antidepressant treatment is a clinically useful predictor of later treatment outcome in patients with major depressive disorders. The aim of this study was to test whether EI can also be used as a predictor for treatment outcome in patients with mild major, minor or subsyndromal depression, i.e. patients, who are typically treated by general practitioners. Methods Analyses were carried out using data from 223 patients of a 10-weeks randomized, placebo-controlled trial comparing the effectiveness of sertraline and cognitive-behavioural therapy (CBT) in patients with mild major, minor or subsyndromal depressio…

AdultMalemedicine.medical_specialtyTime FactorsSeverity of Illness Indexlaw.inventionRandomized controlled trialPredictive Value of TestslawSertralineSurveys and QuestionnairesInternal medicineSeverity of illnessmedicineHumansProspective StudiesPsychiatryProspective cohort studyDepression (differential diagnoses)Depressive DisorderDepressive Disorder MajorSertralineCognitive Behavioral TherapyHamilton Rating Scale for DepressionCombined Modality TherapyAntidepressive AgentsConfidence intervalPsychiatry and Mental healthClinical PsychologyTreatment OutcomePredictive value of testsFemalePsychologymedicine.drugJournal of Affective Disorders
researchProduct

Effects of long-term home-based exercise on health-related quality of life in patients with chronic neck pain: A randomized study with a 1-year follo…

2012

To evaluate whether long-term neck and upper body exercises conducted in economical community-based outpatient clinic and home-based settings could improve health-related quality of life (HRQoL)for individuals affected by chronic neck pain. The effect of baseline HRQoL and neck pain values on training adherence was also studied.Subjects (n = 101, 91 women/10 men, mean age 41.0 ± 9.5 years) with chronic non-specific neck pain were randomized to a combined strength-training and stretching-exercise group (CSSG, n = 49) or to a stretching exercise group (SG, n = 52). HRQoL was assessed at baseline and after 12 months using the RAND-36 questionnaire. Comparisons between groups were performed usi…

AdultMalemedicine.medical_specialtyTime FactorsStrength trainingHealth Statuslaw.inventionChronic neck painRandomized controlled trialQuality of lifelawNeck MusclesmedicineOutpatient clinicHumansMuscle Strengthta315Generalized estimating equationExercisePain MeasurementNeck painNeck Painbusiness.industryRehabilitationChronic painResistance Trainingta3141Middle Agedmedicine.diseaseHome Care ServiceshumanitiesTreatment OutcomePhysical therapyQuality of LifePatient ComplianceFemalemedicine.symptomChronic PainbusinessFollow-Up StudiesDISABILITY AND REHABILITATION
researchProduct

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic …

2007

SummaryTreatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases. Patients with non-familialTTP orAIHA and no underlying malignancy were included in our analysis. Safety and efficacy of R-treatment were compared to results obtained in standard treatment approaches. Altogether, 27 patients were analyzed, comprising 15 patients withTTP and 12 patients with AIHA. The patients’ average age at the time of diagnosis wa…

AdultMalemedicine.medical_specialtyTime FactorsThrombotic thrombocytopenic purpuraSalvage therapyGastroenterologyDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRecurrenceMedian follow-upGermanyhemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProgression-free survivalAgedRetrospective StudiesSalvage TherapyPurpura Thrombocytopenic Idiopathicbusiness.industryStandard treatmentAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeDrug Therapy CombinationFemaleRituximabAnemia Hemolytic AutoimmuneRituximabbusinessFollow-Up Studiesmedicine.drugThrombosis and Haemostasis
researchProduct

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study

2017

AIM To report adalimumab (Ada) efficacy on articular-gastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At baseline, all patients underwent assessment by an integrated gastro-rheumatologic evaluation of articular and gastrointestinal activity, as well patient reported outcomes (PROs) of the HRQoL questionnaires. After this integrated evaluation and following a specific working flowchart, the Ada anti-tumor necrosis factor (TNF)-inhibitor was assigned to a cohort of 30 patients and its clinical efficacy was …

AdultMalemedicine.medical_specialtyTime FactorsTumor necrosis factor-inhibitorMultidisciplinary studyObservational StudyInflammatory bowel diseasesInflammatory bowel diseaseWorkflowEnteropathic spondyloarthriti03 medical and health sciences0302 clinical medicineCrohn DiseaseClinimetric assessmentInternal medicineSpondylarthritisTumor necrosis factor-inhibitorsAdalimumabHumansMedicinePatient Reported Outcome MeasuresPatient reported outcomes030203 arthritis & rheumatologyBiological ProductsTumor Necrosis Factor-alphabusiness.industryRemission InductionAdalimumabGastroenterologyInflammatory Bowel DiseasesGeneral MedicineMiddle AgedPatient reported outcomeEnteropathic spondyloarthritisClinimetric assessment; Enteropathic spondyloarthritis; Inflammatory bowel diseases; Multidisciplinary evaluation; Patient reported outcomes; Tumor necrosis factor-inhibitors; GastroenterologyTreatment OutcomeMultidisciplinary evaluationAntirheumatic AgentsCritical PathwaysQuality of LifeColitis UlcerativeFemale030211 gastroenterology & hepatologyObservational studybusinessmedicine.drug
researchProduct

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

2006

Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a prostacyclin analogue, used, according to a new protocol, in patients with Raynaud’s phenomenon secondary to Systemic Sclerosis. Methods: in this randomized study we treated 30 patients with Iloprost given by intravenous infusion, at progressively increasing doses (starting from 0.5 ng/Kg/min up 2 ng/Kg/min) over a period of 6 hours a day for ten days in two consecutive weeks, with repeated cycles at regular intervals of three months for 18 months. The results were compared with those obtained in 30 other patients, who had received the same drug but with different posologic schemes. Results: …

AdultMalemedicine.medical_specialtyTime FactorsVasodilator AgentsSeverity of Illness IndexDrug Administration ScheduleSclerodermalaw.inventionRheumatologyRandomized controlled trialQuality of lifelawSeverity of illnessmedicineHumansPharmacology (medical)IloprostProspective StudiesDosingInfusions IntravenousProspective cohort studySystemic Sclerosis Raynaud's phenomenon Iloprost Quality of lifeScleroderma SystemicDose-Response Relationship DrugVascular diseasebusiness.industryRaynaud DiseaseMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaQuality of LifeFemalebusinessIloprostmedicine.drugRheumatology
researchProduct

Descriptive and follow-up study of patients treated surgically for abdominal aortic aneurysm at tertiary hospitals in Spain.

2019

BACKGROUND The aim of this study was to assess potential variability in the clinical characteristics and treatment of patients undergoing elective surgery for abdominal aortic aneurysm (AAA) across five hospitals in Spain. METHODS Multicenter, retrospective cohort study of patients diagnosed with AAA and treated with open surgical repair (OSR) or endovascular aneurysm repair (EVAR). We evaluated clinical and demographic variables, including comorbidity (Charlson Comorbidity Index [CCI]); anatomic characteristics; surgical risk (ASA Score); aneurysm characteristics; and in-hospital and overall mortality. All patients were followed for three years. RESULTS A total of 186 patients were include…

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematology030230 surgeryEndovascular aneurysm repairTertiary Care Centers03 medical and health sciencesBlood Vessel Prosthesis Implantation0302 clinical medicineAneurysmPostoperative ComplicationsRisk FactorsmedicineHumansHospital MortalityRisk factorElective surgeryPractice Patterns Physicians'AgedRetrospective StudiesAged 80 and overbusiness.industryMortality ratePatient SelectionEndovascular ProceduresRetrospective cohort studyOdds ratioMiddle Agedmedicine.diseaseAbdominal aortic aneurysmSurgeryLogistic ModelsTreatment OutcomeElective Surgical ProceduresSpainMultivariate AnalysisFemaleCardiology and Cardiovascular MedicinebusinessAortic Aneurysm AbdominalFollow-Up StudiesInternational angiology : a journal of the International Union of Angiology
researchProduct